Novo Nordisk A/s

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Yale University

Medimmune Limited

Madhav N Devalaraja

Chih-Hung Lo

Soumitra S Ghosh

Alan Thomas Remaley

Anna Wolska

Rahul Kakkar

Denis O Sviridov

Michael H Davidson

Jeffrey Testani

Veena Rao

Katherine Jane Escott

Jeffrey Moore Testani

The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.

ApoC-II mimetic peptides

The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.

Methods for treating IL-6 mediated inflammation without immunosuppression

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

Treatment of existing left ventricular heart failure

Growing community of inventors

Acton, MA, United States of America

Madhav N Devalaraja